CN1557325A - 治疗疼痛的药物组合物 - Google Patents
治疗疼痛的药物组合物 Download PDFInfo
- Publication number
- CN1557325A CN1557325A CNA2004100395040A CN200410039504A CN1557325A CN 1557325 A CN1557325 A CN 1557325A CN A2004100395040 A CNA2004100395040 A CN A2004100395040A CN 200410039504 A CN200410039504 A CN 200410039504A CN 1557325 A CN1557325 A CN 1557325A
- Authority
- CN
- China
- Prior art keywords
- domperidone
- benorylate
- pain
- pharmaceutical composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 230000003119 painkilling effect Effects 0.000 title 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims abstract description 122
- 229960001253 domperidone Drugs 0.000 claims abstract description 122
- FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 claims abstract description 113
- 229960004277 benorilate Drugs 0.000 claims abstract description 113
- 208000002193 Pain Diseases 0.000 claims abstract description 90
- 230000036407 pain Effects 0.000 claims abstract description 90
- 239000000203 mixture Substances 0.000 claims abstract description 66
- 206010013935 Dysmenorrhoea Diseases 0.000 claims abstract description 42
- 208000005171 Dysmenorrhea Diseases 0.000 claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims description 44
- 238000002360 preparation method Methods 0.000 claims description 40
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 37
- 208000019695 Migraine disease Diseases 0.000 claims description 37
- 206010027599 migraine Diseases 0.000 claims description 37
- 229940069428 antacid Drugs 0.000 claims description 35
- 239000003159 antacid agent Substances 0.000 claims description 35
- 230000001458 anti-acid effect Effects 0.000 claims description 35
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 31
- 230000002265 prevention Effects 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 22
- 206010019233 Headaches Diseases 0.000 abstract description 14
- 239000003826 tablet Substances 0.000 description 32
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 30
- 229920002472 Starch Polymers 0.000 description 29
- 239000008107 starch Substances 0.000 description 29
- 235000019698 starch Nutrition 0.000 description 29
- 208000024891 symptom Diseases 0.000 description 29
- 229940079593 drug Drugs 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 206010047700 Vomiting Diseases 0.000 description 22
- 238000009472 formulation Methods 0.000 description 22
- 239000008187 granular material Substances 0.000 description 21
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 239000008108 microcrystalline cellulose Substances 0.000 description 20
- 229940016286 microcrystalline cellulose Drugs 0.000 description 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 206010025482 malaise Diseases 0.000 description 18
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 18
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 18
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 17
- 239000000395 magnesium oxide Substances 0.000 description 16
- 206010000059 abdominal discomfort Diseases 0.000 description 15
- 235000019359 magnesium stearate Nutrition 0.000 description 15
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 14
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 231100000869 headache Toxicity 0.000 description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 201000006549 dyspepsia Diseases 0.000 description 11
- 208000024798 heartburn Diseases 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 11
- 229960004793 sucrose Drugs 0.000 description 11
- 230000008673 vomiting Effects 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 229960005489 paracetamol Drugs 0.000 description 8
- 206010034960 Photophobia Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000000829 suppository Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 239000007902 hard capsule Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000004925 Acrylic resin Substances 0.000 description 5
- 229920000178 Acrylic resin Polymers 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 206010067171 Regurgitation Diseases 0.000 description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000003821 menstrual periods Effects 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000007910 chewable tablet Substances 0.000 description 4
- 229940068682 chewable tablet Drugs 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 239000007919 dispersible tablet Substances 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 3
- 206010006784 Burning sensation Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940000425 combination drug Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940020465 domperidone 10 mg Drugs 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 229960000869 magnesium oxide Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 238000005453 pelletization Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000004206 stomach function Effects 0.000 description 3
- 150000003445 sucroses Chemical class 0.000 description 3
- 239000002511 suppository base Substances 0.000 description 3
- 239000007939 sustained release tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010034962 Photopsia Diseases 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002460 anti-migrenic effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- -1 fluidizer Substances 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960004503 metoclopramide Drugs 0.000 description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
- KJBLQGHJOCAOJP-UHFFFAOYSA-N metoclopramide hydrochloride Chemical compound O.Cl.CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC KJBLQGHJOCAOJP-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- BCHLTFOMLWCYIS-UHFFFAOYSA-N 4-amino-5-chloro-n-[2-(diethylamino)ethyl]-2-methoxybenzamide;n-(4-hydroxyphenyl)acetamide;hydrochloride Chemical compound Cl.CC(=O)NC1=CC=C(O)C=C1.CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC BCHLTFOMLWCYIS-UHFFFAOYSA-N 0.000 description 1
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010063341 Metamorphopsia Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940086219 acetaminophen 250 mg Drugs 0.000 description 1
- 229940086239 acetaminophen 500 mg Drugs 0.000 description 1
- 229940068372 acetyl salicylate Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940085430 aspirin 300 mg Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 210000000162 simple eye Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 208000018770 vision symptom Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
药品 | 痛症 | 胃肠不适症 |
A药 | 1).8人于首次用药后疼痛缓解,其中7人在8小时后疼痛消失,1人治疗期间仍有较弱的痛感;2).4人在治疗期间疼痛无明显的缓解。 | 1).7人用药期间和用完药后2天内均无胃肠不适。2).5人在治疗期间有较弱的恶心和呕吐感。其中1人还有2次呕吐。 |
B药 | 1).7人于首次用药后疼痛缓解,其中5人在8小时后疼痛消失,2人治疗期间仍有较弱的痛感;2).5人在治疗期间疼痛无明显的缓解。 | 1).5人用药期间和用完药后2天内均无胃肠不适。2).7人在治疗期间有较弱的恶心和呕吐感,其中2人还有胃灼烧感。 |
C药 | 1).11人于首次用药后疼痛缓解,其中10人在8小时后疼痛消失,1人治疗期间仍有较弱的痛感;2).1人在治疗期间疼痛无明显的缓解。 | 1).10人用药期间和用完药后2天内均无胃肠不适。2).2人在治疗期间有较弱的恶心和呕吐感。 |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410039504 CN1239162C (zh) | 2004-02-05 | 2004-02-05 | 治疗疼痛的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410039504 CN1239162C (zh) | 2004-02-05 | 2004-02-05 | 治疗疼痛的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1557325A true CN1557325A (zh) | 2004-12-29 |
CN1239162C CN1239162C (zh) | 2006-02-01 |
Family
ID=34352336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410039504 Expired - Lifetime CN1239162C (zh) | 2004-02-05 | 2004-02-05 | 治疗疼痛的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1239162C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102307575B (zh) * | 2009-02-04 | 2013-02-13 | 韩国联合制药株式会社 | 含醋氯芬酸的控释口服药制剂及其制造方法 |
-
2004
- 2004-02-05 CN CN 200410039504 patent/CN1239162C/zh not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102307575B (zh) * | 2009-02-04 | 2013-02-13 | 韩国联合制药株式会社 | 含醋氯芬酸的控释口服药制剂及其制造方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1239162C (zh) | 2006-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1171582C (zh) | 口服药用延释剂型 | |
CN1149077C (zh) | 快速崩解固体制剂 | |
CN1703203A (zh) | 感官可接受的口腔内崩解组合物 | |
CN1284867A (zh) | 生产咀嚼分散片的方法 | |
JP5702305B2 (ja) | 有核型の口腔内崩壊錠 | |
CN1551768A (zh) | 新型取代的苯并咪唑剂型及其应用方法 | |
CN1376146A (zh) | 提高了生物利用率的雪列柯西的固态形式 | |
CN1433309A (zh) | 环加氧酶-2抑制剂的二元释放组合物 | |
CN1679525A (zh) | 复方对乙酰氨基酚口腔崩解片 | |
CN1589906A (zh) | 5ht4激动剂或拮抗剂的新型口服制剂 | |
CN1765362A (zh) | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 | |
JP2001517626A (ja) | 呼吸疾患を治療するための組成物及び方法 | |
CN1527700A (zh) | 制备苯妥英钠剂型的压缩方法 | |
CN1625405A (zh) | 包含环加氧酶-2抑制剂和阿司匹林的组合 | |
CN1723964A (zh) | 一种治疗咳喘、慢性支气管炎的药物 | |
CN1446535A (zh) | 盐酸[R-(Z)]-α-甲氧亚氨基-α-(1-氮杂双环[2.2.2]辛-3-基)乙腈控释剂型 | |
CN1239162C (zh) | 治疗疼痛的药物组合物 | |
CN1499961A (zh) | 一种在胃液中漂浮并多脉冲释放活性物质的药用片剂系统、该系统和该系统包封物的制备方法 | |
CN1269480C (zh) | 氯雷他定口腔崩解片及其制备方法 | |
CN1861064A (zh) | 一种含有薁磺酸钠与l-谷氨酰胺水溶性前体药物的组合物 | |
EP2682109B1 (en) | Combined immediate release formulations of flurbiprofen and famotidine | |
CN1631358A (zh) | 含有盐酸伪麻黄碱的治疗感冒的复方散剂及其处方和制备方法 | |
CN1724013A (zh) | 一种治疗胸痹的中药制剂 | |
CN1650929A (zh) | 一种万通筋骨制剂及其制备方法 | |
CN1923182A (zh) | 拉西地平口腔崩解片制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090320 Address after: Jinxi road Binhu District of Jiangsu city of Wuxi province No. 100 Patentee after: Xu Xiaochun Address before: Room 702, building 3, building 3, building two, Beijing Town, Xiyuan District, Changping District Patentee before: Yan Siping |
|
ASS | Succession or assignment of patent right |
Owner name: XU XIAOCHUN Free format text: FORMER OWNER: YAN SIPING Effective date: 20090320 |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Xu Xiaochun Document name: Notification of Passing Examination on Formalities |
|
ASS | Succession or assignment of patent right |
Owner name: WUXI BOYA BIOENGINEERING CO., LTD. Free format text: FORMER OWNER: XU XIAOCHUN Effective date: 20100824 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 214081 NO. 100, JINXI ROAD, BINHU DISTRICT, WUXI CITY, JIANGSU PROVINCE TO: 214092 NO. 88, MASHANMEILIANG ROAD, BINHU DISTRICT, WUXI CITY, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100824 Address after: Ma Shan Mei Binhu District 214092 in Jiangsu province Wuxi City Road No. 88 beam Patentee after: Wuxi Boya Bio-technology Co.,Ltd. Address before: Jinxi road Binhu District 214081 Jiangsu city of Wuxi province No. 100 Patentee before: Xu Xiaochun |
|
C56 | Change in the name or address of the patentee |
Owner name: BOYALIFE STEM CELL TECHNOLOGY CO., LTD. Free format text: FORMER NAME: WUXI BOYALIFE BIOENGINEERING CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Ma Shan Mei Binhu District 214092 in Jiangsu province Wuxi City Road No. 88 beam Patentee after: BOYALIFE Inc. Address before: Ma Shan Mei Binhu District 214092 in Jiangsu province Wuxi City Road No. 88 beam Patentee before: Wuxi Boya Bio-technology Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: GUANGDONG BOYA STEM CELL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BOYA STEM CELLS TECHNOLOGY CO., LTD. Effective date: 20141125 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 214092 WUXI, JIANGSU PROVINCE TO: 528000 FOSHAN, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141125 Address after: 528000 Guangdong Province, Foshan city Chancheng District ancient road No. 70 Foshan high tech Zone Science and Technology Industrial Park D building 201 unit Patentee after: Guangdong Boya Stem Cell Technology Co.,Ltd. Address before: Ma Shan Mei Binhu District 214092 in Jiangsu province Wuxi City Road No. 88 beam Patentee before: BOYALIFE Inc. |
|
DD01 | Delivery of document by public notice |
Addressee: Guangdong Boya Stem Cell Technology Co.,Ltd. Document name: Notification that Application Deemed not to be Proposed |
|
DD01 | Delivery of document by public notice |
Addressee: Guangdong Boya Stem Cell Technology Co.,Ltd. Document name: Deemed not to advise |
|
ASS | Succession or assignment of patent right |
Owner name: BOYA STEM CELLS TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: GUANGDONG BOYA STEM CELL TECHNOLOGY CO., LTD. Effective date: 20150413 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 528000 FOSHAN, GUANGDONG PROVINCE TO: 214092 WUXI, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150413 Address after: Ma Shan Mei Binhu District 214092 in Jiangsu province Wuxi City Road No. 88 beam Patentee after: BOYALIFE Inc. Address before: 528000 Guangdong Province, Foshan city Chancheng District ancient road No. 70 Foshan high tech Zone Science and Technology Industrial Park D building 201 unit Patentee before: Guangdong Boya Stem Cell Technology Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: YINGKE BOYA GROUP CO., LTD. Free format text: FORMER OWNER: BOYA STEM CELLS TECHNOLOGY CO., LTD. Effective date: 20150615 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150615 Address after: 214000 No. 800 Jiefang East Road, Nanchang District, Jiangsu, Wuxi Patentee after: SINICA GROUP CO.,LTD. Address before: Ma Shan Mei Binhu District 214092 in Jiangsu province Wuxi City Road No. 88 beam Patentee before: BOYALIFE Inc. |
|
CX01 | Expiry of patent term |
Granted publication date: 20060201 |
|
CX01 | Expiry of patent term |